Moderna secured its spot on the South Korean market

May 24, 2021
Moderna secured its spot on the South Korean market

The week started with a deal in the pharma sector regarding the manufacturing of Moderna’s COVID-19 vaccine

Moderna and Novavax agreed with the South Korean government to manufacture the vaccine, as the country has lately been under pressure to secure more and faster deliveries. South Korea confirmed access to 40 million doses, according to authorities.

The agreement came after the US and the South Korean presidents – Joe Biden and Moon Hae-in – agreed on a partnership through which the first will provide vaccinations for 550,000 South Korean soldiers. The partnership will combine the US expertise and Korean manufacturing capacity.

Moderna and Novavax are not the first pharma companies to close this deal with the South Korean government. Among the COVID-19 vaccine produced there are AstraZeneca’s and Russia’s Sputnik V.

So far, the country has vaccinated less than 10% of its 52 million people. By September, it aims to inoculate at least 70%. Overall, it ordered approx. 192 million vaccine doses from AstraZeneca, Pfizer, Novavax, Moderna, Johnson & Johnson.

Following the news, Moderna stock price went up 1.6%.


This information prepared by is not an offer or a solicitation for the purpose of purchase or sale of any financial products referred to herein or to enter into any legal relations, nor an advice or a recommendation with respect to such financial products.
This information is prepared for general circulation. It does not have regard to the specific investment objectives, financial situation or the particular needs of any recipient.

You should independently evaluate each financial product and consider the suitability of such a financial product, by taking into account your specific investment objectives, financial situation or particular needs, and by consulting an independent financial adviser as needed, before dealing in any financial products mentioned in this document.

This information may not be published, circulated, reproduced or distributed in whole or in part to any other person without the Company’s prior written consent.
Past performance is not always indicative of likely or future performance. Any views or opinions presented are solely those of the author and do not necessarily represent those of

Recently Added